The media have labelled Ozempic as a weight loss drug and it can sometimes be prescribed off-label for this purpose
Excitotoxicity : Excessive glutamate release resulting in sodium and calcium influx, which impairs neuronal viability
Whilst the market is currently led by Novo Nordisks semaglutide (Ozempic/Wegovy) and Eli Lillys tirzepatide (Mounjaro/Zepbound), stronger competition is expected with new entrants (Boehringer Ingelheim, Amgen, Pfizer, Roche amongst others) offering novel mechanisms (dual agonists, triple agonists and amylins), formulations (oral vs injectable) and dosing regimens (daily vs weekly vs monthly).
This guide provides evidence-based recommendations on food selection, meal planning, and managing common gastrointestinal symptoms to help you achieve the best outcomes during semaglutide therapy
Artificial intelligence in dentistry: exploring emerging applications and future prospects